Target	Disease	Drug_index	Drug
TNF	Arthritis	1	adalimumab [TNF-alpha inhibitor]
TNF	Ankylosing Spondylitis	2	adalimumab [TNF-alpha inhibitor], certolizumab pegol [TNF-alpha inhibitor], etanercept [TNF-alpha inhibitor], golimumab [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
TNF	Psoriatic Arthritis	2	adalimumab [TNF-alpha inhibitor], certolizumab pegol [TNF-alpha inhibitor], etanercept [TNF-alpha inhibitor], golimumab [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
TNF	Rheumatoid Arthritis	2	adalimumab [TNF-alpha inhibitor], certolizumab pegol [TNF-alpha inhibitor], etanercept [TNF-alpha inhibitor], golimumab [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
TNF	Psoriasis	3	adalimumab [TNF-alpha inhibitor], etanercept [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
TNF	Ulcerative Colitis	4	adalimumab [TNF-alpha inhibitor], golimumab [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
EGFR	Non-Small Cell Lung Carcinoma	5	afatinib dimaleate [Epidermal growth factor receptor erbB1 inhibitor], amivantamab [Epidermal growth factor receptor inhibitor], brigatinib [Epidermal growth factor receptor erbB1 inhibitor], dacomitinib [Epidermal growth factor receptor erbB1 inhibitor], erlotinib hydrochloride [Epidermal growth factor receptor erbB1 inhibitor], gefitinib [Epidermal growth factor receptor erbB1 inhibitor], necitumumab [Epidermal growth factor receptor erbB1 inhibitor], osimertinib [Epidermal growth factor receptor erbB1 inhibitor], osimertinib mesylate [Epidermal growth factor receptor erbB1 inhibitor]
ERBB2	Non-Small Cell Lung Carcinoma	6	afatinib dimaleate [Receptor protein-tyrosine kinase erbB-2 inhibitor], dacomitinib [Receptor protein-tyrosine kinase erbB-2 inhibitor]
IL2RA	Cutaneous Melanoma	7	aldesleukin [Interleukin-2 receptor agonist]
IL2RA	Melanoma	7	aldesleukin [Interleukin-2 receptor agonist]
IL2RA	Metastatic Melanoma	7	aldesleukin [Interleukin-2 receptor agonist]
JAK1	Rheumatoid Arthritis	8	baricitinib [Tyrosine-protein kinase JAK1 inhibitor], tofacitinib citrate [Janus Kinase (JAK) inhibitor], upadacitinib [Janus Kinase (JAK) inhibitor]
JAK2	Rheumatoid Arthritis	9	baricitinib [Tyrosine-protein kinase JAK2 inhibitor], tofacitinib citrate [Janus Kinase (JAK) inhibitor], upadacitinib [Janus Kinase (JAK) inhibitor]
SRC	Chronic Myelogenous Leukemia	10	bosutinib [Tyrosine-protein kinase SRC inhibitor]
TNF	Inflammation	11	certolizumab pegol [TNF-alpha inhibitor]
TNF	Crohn's Disease	12	certolizumab pegol [TNF-alpha inhibitor], infliximab [TNF-alpha inhibitor]
EGFR	Head And Neck Carcinoma	13	cetuximab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Head And Neck Malignant Neoplasia	13	cetuximab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Head And Neck Squamous Cell Carcinoma	13	cetuximab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Malignant Tumor Of Neck	13	cetuximab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Squamous Cell Carcinoma	13	cetuximab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Colorectal Adenocarcinoma	14	cetuximab [Epidermal growth factor receptor erbB1 inhibitor], panitumumab [Epidermal growth factor receptor erbB1 inhibitor]
EGFR	Colorectal Carcinoma	14	cetuximab [Epidermal growth factor receptor erbB1 inhibitor], panitumumab [Epidermal growth factor receptor erbB1 inhibitor]
IL2RA	Relapsing-Remitting Multiple Sclerosis	15	daclizumab [Interleukin-2 receptor inhibitor]
IL2RA	Cutaneous T-Cell Lymphoma	16	denileukin diftitox [Interleukin-2 receptor binding agent]
TNF	Juvenile Idiopathic Arthritis	17	etanercept [TNF-alpha inhibitor]
TNF	Psoriasis Vulgaris	17	etanercept [TNF-alpha inhibitor]
TNF	Spondylitis	18	etanercept [TNF-alpha inhibitor], golimumab [TNF-alpha inhibitor]
JAK2	Myelofibrosis	19	fedratinib hydrochloride [Tyrosine-protein kinase JAK2 inhibitor], ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor]
JAK2	Primary Myelofibrosis	19	fedratinib hydrochloride [Tyrosine-protein kinase JAK2 inhibitor], ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor]
IL12B	Pustulosis Palmaris Et Plantaris	20	guselkumab [Interleukin-23 inhibitor], risankizumab [Interleukin-23 inhibitor]
IL12B	Psoriasis	21	guselkumab [Interleukin-23 inhibitor], risankizumab [Interleukin-23 inhibitor], tildrakizumab [Interleukin-23 inhibitor], ustekinumab [Interleukin-12 inhibitor], ustekinumab [Interleukin-23 inhibitor]
IL12B	Psoriasis Vulgaris	22	guselkumab [Interleukin-23 inhibitor], tildrakizumab [Interleukin-23 inhibitor], ustekinumab [Interleukin-12 inhibitor], ustekinumab [Interleukin-23 inhibitor]
IL12B	Psoriatic Arthritis	23	guselkumab [Interleukin-23 inhibitor], ustekinumab [Interleukin-12 inhibitor], ustekinumab [Interleukin-23 inhibitor]
EGFR	Breast Carcinoma	24	lapatinib ditosylate [Epidermal growth factor receptor erbB1 inhibitor], neratinib maleate [Epidermal growth factor receptor erbB1 inhibitor]
ERBB2	Breast Carcinoma	25	lapatinib ditosylate [Receptor protein-tyrosine kinase erbB-2 inhibitor], neratinib maleate [Receptor protein-tyrosine kinase erbB-2 inhibitor], pertuzumab [Receptor protein-tyrosine kinase erbB-2 inhibitor], trastuzumab [Receptor protein-tyrosine kinase erbB-2 inhibitor], trastuzumab deruxtecan [Receptor protein-tyrosine kinase erbB-2 binding agent], trastuzumab emtansine [Receptor protein-tyrosine kinase erbB-2 inhibitor], tucatinib [Receptor protein-tyrosine kinase erbB-2 inhibitor]
JAK1	Myelofibrosis	26	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor]
JAK1	Polycythemia Vera	26	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor]
JAK1	Primary Myelofibrosis	26	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor]
JAK2	Polycythemia Vera	27	ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor]
IL6R	Rheumatoid Arthritis	28	sarilumab [Interleukin-6 receptor alpha subunit antagonist], tocilizumab [Interleukin-6 receptor alpha subunit inhibitor]
IL6R	Neuromyelitis Optica	29	satralizumab [IL6Ralpha/GP130 antagonist]
SRC	Actinic Keratosis	30	tirbanibulin [Tyrosine-protein kinase SRC inhibitor]
IL6R	Juvenile Idiopathic Arthritis	31	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor]
IL6R	Systemic Scleroderma	31	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor]
IL6R	Temporal Arteritis	31	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor]
TYK2	Psoriatic Arthritis	32	tofacitinib citrate [Janus Kinase (JAK) inhibitor]
JAK3	Psoriatic Arthritis	32	tofacitinib citrate [Janus Kinase (JAK) inhibitor]
JAK2	Psoriatic Arthritis	32	tofacitinib citrate [Janus Kinase (JAK) inhibitor]
JAK1	Psoriatic Arthritis	32	tofacitinib citrate [Janus Kinase (JAK) inhibitor]
TYK2	Rheumatoid Arthritis	33	tofacitinib citrate [Janus Kinase (JAK) inhibitor], upadacitinib [Janus Kinase (JAK) inhibitor]
JAK3	Rheumatoid Arthritis	33	tofacitinib citrate [Janus Kinase (JAK) inhibitor], upadacitinib [Janus Kinase (JAK) inhibitor]
ERBB2	Her2 Positive Breast Carcinoma	34	tucatinib [Receptor protein-tyrosine kinase erbB-2 inhibitor]
IL12B	Crohn's Disease	35	ustekinumab [Interleukin-12 inhibitor], ustekinumab [Interleukin-23 inhibitor]
ERBB2	Medullary Thyroid Gland Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
EGFR	Medullary Thyroid Gland Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
ERBB2	Papillary Thyroid Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
EGFR	Papillary Thyroid Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
ERBB2	Thyroid Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
EGFR	Thyroid Carcinoma	36	vandetanib [Epidermal growth factor receptor inhibitor]
SRC	Medullary Thyroid Gland Carcinoma	37	vandetanib [Tyrosine-protein kinase SRC inhibitor]
SRC	Papillary Thyroid Carcinoma	37	vandetanib [Tyrosine-protein kinase SRC inhibitor]
SRC	Thyroid Carcinoma	37	vandetanib [Tyrosine-protein kinase SRC inhibitor]